Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/07/2017 12/08/2017 12/11/2017 12/12/2017 12/13/2017 Date
4.17(c) 4(c) 4.2(c) 4.17(c) 4.19 Last
2 075 017 1 321 413 1 358 506 565 840 365 956 Volume
+3.99% -4.08% +5.00% -0.71% +0.48% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -18,8 M
Net income 2017 -18,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,17 M
EBIT 2018 -26,1 M
Net income 2018 -25,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 50,1x
Capitalization 359 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
12/04 CATALYST PHARMACEUTICALS : Announces Closing of Previously Announced Public Offe..
12/01 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
11/30 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
11/30 Catalyst Pharmaceuticals, Inc. Announces Closing of Previously Announced Publ..
11/29 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Entry into a Material ..
11/28 CATALYST PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Fin..
11/28 CATALYST PHARMACEUTICALS, INC. : Prices Previously Announced Public Offering of ..
11/28 CATALYST PHARMACEUTICALS : Announces Positive Top Line Results from Second Phase..
11/28 REGENERON PHARMACEUTICALS, INC. (NAS : REGN) And Catalyst Pharmaceuticals, Inc. ..
11/28 CATALYST PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock
More news
Sector news : Bio Therapeutic Drugs
04:24p France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06:43a YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/08 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,19 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC280.95%361
GILEAD SCIENCES3.64%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS94.94%35 831
GENMAB0.85%11 452
BLUEBIRD BIO INC177.39%9 249